“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”

Sergio Palmeri

“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Other

Lingua originale	English
Numero di pagine	1
Stato di pubblicazione	Published - 2009

Cita questo

Palmeri, S. (2009). “Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”.

@conference{cb0d472329d54f2991f4e34a5a679820,

title = "“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”",

keywords = "bevacizumab, metastatic colorectal cancer, bevacizumab, metastatic colorectal cancer",

author = "Sergio Palmeri",

year = "2009",

language = "English",

}

TY - CONF

T1 - “Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”

AU - Palmeri, Sergio

PY - 2009

Y1 - 2009

KW - bevacizumab

KW - metastatic colorectal cancer

KW - bevacizumab

KW - metastatic colorectal cancer

UR - http://hdl.handle.net/10447/45274

M3 - Other

ER -

Accesso al documento

OA Link